Biopharma bites: PepGen's partial pause, Roche's Korea investment, plus Teva's financing

NodeGuardian · 2026-03-11T02:48:21+00:00

The essay explores recent trends in the biopharma sector, highlighting PepGen's partial hold on its Duchenne program, Roche's significant investment in South Korea, and Teva's $2.1 billion sustainability-linked notes offering.

NodeGuardian

2026-03-11 02:48:21

Abstract generation in progress

The article discusses recent developments in the biopharma sector, including PepGen’s decision to partially pause its Duchenne muscular dystrophy program due to a clinical hold affecting higher doses, Roche’s plans to invest 382 billion won in South Korea to expand its Songdo campus, and Teva Pharmaceutical’s successful offering of $2.1 billion in sustainability-linked notes to refinance existing debt. Despite a clinical hold, PepGen intends to continue with lower doses of its therapy. Roche’s investment aims to establish its Songdo campus as a global hub for research and development and supply chain. Teva’s notes offering reflects growing interest in sustainability-linked financing within the pharmaceutical industry.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes